ResearcherNational and Kapodistrian University of AthensActive in the last 2 years
Maximos Frountzas
Matched on ORCID iD 0000-0001-9157-9860; OpenAlex author ID A5075255744. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 3, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers
Papers 6
- Emerging Tumor Biomarkers in Pancreatic Cancer and Their Clinical Implications. First author DOI 10.3390/cimb47050347↗
- Exploring the Link Between Nutritional and Functional Status and Short-Term Postoperative Outcomes in Patients Undergoing Pancreatic Cancer Surgery. First author DOI 10.3390/life15050803↗
- Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer. First author DOI 10.3390/cimb46040177↗
- "Oligometastatic pancreatic cancer" definition: The first step. Co-author DOI 10.1016/j.hbpd.2022.07.002↗
- The impact of surgery delay on survival of resectable pancreatic cancer: A systematic review of observational studies. Co-author DOI 10.1016/j.suronc.2022.101855↗
- Immunotherapy in Combination with Well-Established Treatment Strategies in Pancreatic Cancer: Current Insights. Co-author DOI 10.2147/cmar.s267260↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Dimitriοs Schizas · 6 shared papers, 2022–2025 · strength 1.40
- Paper Emerging Tumor Biomarkers in Pancreatic Cancer and Their Clinical Implications. DOI 10.3390/cimb47050347↗
- Paper "Oligometastatic pancreatic cancer" definition: The first step. DOI 10.1016/j.hbpd.2022.07.002↗
- Paper Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer. DOI 10.3390/cimb46040177↗
- Konstantinos G. Toutouzas · 5 shared papers, 2022–2025 · strength 1.22
- Paper Emerging Tumor Biomarkers in Pancreatic Cancer and Their Clinical Implications. DOI 10.3390/cimb47050347↗
- Paper "Oligometastatic pancreatic cancer" definition: The first step. DOI 10.1016/j.hbpd.2022.07.002↗
- Paper Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer. DOI 10.3390/cimb46040177↗
- Dimitrios Stefanoudakis · 3 shared papers, 2024–2025 · strength 0.78
- Paper Emerging Tumor Biomarkers in Pancreatic Cancer and Their Clinical Implications. DOI 10.3390/cimb47050347↗
- Paper Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer. DOI 10.3390/cimb46040177↗
- Paper Exploring the Link Between Nutritional and Functional Status and Short-Term Postoperative Outcomes in Patients Undergoi… DOI 10.3390/life15050803↗
- Michail G. Vailas · 2 shared papers, 2022–2025 · strength 0.39
- Paper Exploring the Link Between Nutritional and Functional Status and Short-Term Postoperative Outcomes in Patients Undergoi… DOI 10.3390/life15050803↗
- Paper The impact of surgery delay on survival of resectable pancreatic cancer: A systematic review of observational studies. DOI 10.1016/j.suronc.2022.101855↗
- Alexandra Drakaki · 1 shared paper, 2024 · strength 0.26
- Evangelos S. Felekouras · 1 shared paper, 2025 · strength 0.22
- Irene Lidoriki · 1 shared paper, 2025 · strength 0.22
- Christo Kole · 1 shared paper, 2022 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.